



General Assembly Meeting

President's Activity Report
Treasurer's Activity Report
Secretary's Report
Election and re-election results
Strategic Plan

Mohamad Mohty
Fred Falkenburg
Anna Sureda
Anna Sureda
Mohamad Mohty

Istanbul – Tuesday 24 March 2015




President's Activity Report

Mohamad Mohty

Istanbul – Tuesday 24 March 2015

About the European Society for Blood and Marrow Transplantation (EBMT)



“Change is difficult, but necessary...”: recent changes in EBMT

- **Structure of the Annual Meeting**
- **Registry upgrade**
- **Use of Social Media:**
 - **Creation of the @TheEBMT corporate Twitter account allowing interaction and information sharing with the transplant community**
 - ***Social media special session* on Monday 23rd March at 9.00am in Üsküdar Hall**





EBMT's achievements

Last year achievements



SCIENCE

- **223** studies/projects ongoing
- **69** publications in peer-reviewed journals
- **36,940** registered transplants in the Registry



EDUCATION

- **12** educational events
- **4625** delegates at EBMT 2014



ACCREDITATION

- **52** applications received and **50** inspections performed
- **47** accreditations awarded

2 trials are recruiting patients / in set-up phase:

- AAWP : **RACE** compares standard IST (ATG + CsA) plus Eltrombopag vs Standard IST alone.
 - This EBMT study is financially supported by GSK and Pfizer. 31 EBMT Centres will enroll patients. The study is in the set-up phase with EC and CA submissions ongoing. First patient in planned for May 2015 in France/Italy.
- CQWP/IDWP : **CMV prophylaxis** phase III RCT to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of CMV Infection in adult, CMV-Seropositive Allogeneic HSCT Recipients.
 - This Merck sponsored trial is supported by the EBMT (recruitment and retention services) – 158 out of 540 patients have been recruited.

2 trials were published in the last year:

- ADWP : **ASTIS** was published in 2014 in JAMA and long-term follow-up (5 years) completes in 2017. **ASTIMS** was published in 2015 in Neurology and is now complete.
- The CT2 committee is open for new CT proposals (deadline = 17 Apr 15)

- Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Passweg JR et al. *Bone Marrow Transplant*. 2015 Feb
 - 39 209 HSCT in 34 809 patients were reported by 658 centers in 48 countries to the 2013 survey.
- **Trends:**
 - More growth in allogeneic than in autologous HSCT
 - Increasing use of sibling and unrelated donors
 - Pronounced increase in haploidentical family donors when compared with cord blood donors.
- **Main indications:**
 - Leukemias: 11,190
 - lymphoid diseases: 19,958
 - solid tumors: 1,543
 - Non-malignant disorders: 1,975

SPECIAL REPORT

Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015


A Sureda¹, P Bader², S Cesaro³, P Dreger⁴, RF Duarte¹, C Dufour⁵, JHF Falkenburg⁶, D Farge-Bancel⁷, A Gennery⁸, N Kröger⁹, F Lanza¹⁰, JC Marsh¹¹, A Nagler¹², C Peters¹³, A Velardi¹⁴, M Mohty^{15,17} and A Madrigal^{16,17} for the European Society for Blood and Marrow Transplantation

This is the sixth special report that the European Society for Blood and Marrow Transplantation regularly publishes on the current practice and indications for haematopoietic SCT for haematological diseases, solid tumours and immune disorders in Europe. Major changes have occurred in the field of haematopoietic SCT over the last years. Cord blood units as well as haploidentical donors have been increasingly used as stem cell sources for allo-SCT, thus, augmenting the possibility of finding a suitable donor for a patient. Continuous refinement of conditioning strategies has also expanded not only the number of potential indications but also has permitted consideration of older patients or those with co-morbidity for a transplant. There is accumulating evidence of the role of haematopoietic SCT in non-haematological disorders such as autoimmune diseases. On the other hand, the advent of new drugs and very effective targeted therapy has challenged the role of SCT in some instances or at least, modified its position in the treatment armamentarium of a given patient. An updated report with revised tables and operating definitions is presented.

Bone Marrow Transplantation advance online publication, 16 March 2015; doi:10.1038/bmt.2015.6

Disease	Patients	Transplants
Acute leukaemias: AML	64,257	70,472
Acute leukaemias: ALL	40,179	43,303
Acute leukaemias: other/unknown	2,317	2,597
Chronic leukaemias: CML	20,705	22,309
Chronic leukaemias: CLL	6,221	6,866
Chronic leukaemias: other/unknown	764	847
Lymphomas: NHL	85,669	95,242
Lymphomas: Hodgkins	29,585	34,095
Lymphomas: other/unknown	1,646	1,752
Multiple myeloma/Plasma cell disorders	94,163	127,573
Solid tumours	38,857	52,312
Myelodysplastic/myeloproliferative	28,610	32,225
BM Failure syndromes including AA	10,585	11,656
Primary immune deficiency	4,416	5,016
Inborn errors: other / unspecified	2,016	2,270
Histiocytic	1,141	1,255
Autoimmune diseases	1,793	1,842
Haemoglobinopathies	5,114	5,385
Other/unknown	185	212
Total	438,223	517,229

Type of transplant by year



- **Important setback during 2014**
 - In October, Remedy ceased business and their assets were eventually auctioned.
- **The project is on hold**
 - Negotiations with the new company to see whether they can continue with the project.
 - The EBMT is maintaining communication with other clients that were left in the same situation and is open to approaches from other possible providers.
- **Move to ProMISe version 3**
 - Enhanced security features and some extra functionality.
 - Underlying structure and database are the same as in the previous version.

EBMT educational events: Mark your calendar!

EDUCATION

24 April 2015

EBMT Inborn Errors Working Party Workshop - How to transplant a patient with Primary Immunodeficiency
Leuven, Belgium

14 - 17 May 2015

5th EBMT training course for paediatricians and paediatric nurses on HSCT in children and adolescents
Marrakesh, Morocco

21 - 23 May 2015

9th edition of the ESH - EBMT Training Course on Haemopoietic Stem Cell Transplantation
Málaga, Spain

26 - 29 May 2015

3rd edition of the EBMT Statistical Course
Leiden, The Netherlands



25 - 26 September 2015

11th Educational Course of the Lymphoma Working Party on "Treatment of Malignant Lymphoma: State-of-the-Art and Role of Stem Cell Transplantation"

Heidelberg, Germany

1 - 2 October 2015

JACIE Inspector Training Course
Barcelona, Spain

9 October 2015

EBMT Nurses Group International Study Day
Pilsen (Plzeň), Czech Republic

16 - 18 October 2015

ESID - EBMT Inborn Errors Working Party Conference
Seville, Spain

29 - 30 October 2015

Thinking Outside the Box: going beyond 'Survival after Stem Cell Transplant' a Complications and Quality of Life Working Party Educational Course
Leuven, Belgium

20 - 21 November 2015

Autoimmune Diseases Working Party Educational Course and Business Meeting
Berlin, Germany




For more information please consult
www.ebmt.org/events



JACIE


Current accreditations


ACCREDITATION



- Initial accreditation (107)
- Reaccreditation 1 (58)
- ◆ Reaccreditation 2 (10)



 = JACIE accreditation is a requirement for authorisation or reimbursement





EBMT Annual Meeting

- **4387** delegates
- **16** physicians symposia
- **1** nurses symposia
- **4** lunch controversies
- **2** spotlight sessions
- **20** educational sessions
- **17** workshops
- **11** working party sessions
- **40** sponsored booths
- **1326** abstracts have been received

- **Opening session**
 - **Van Bekkum Award** – *sponsored by EBMT*
 - **Basic Science Award** – *sponsored by Clinigen*
- **Presidential symposium**
 - **Honorary Members**
 - **Outgoing Board Member(s)**
- **Lymphoma Working Party session**
 - **Jian-Jian Luan for Lymphoma Transplant Research** – *sponsored by the EBMT LWP*
- **Immunobiology Working Party session**
 - **Jon J. van Rood Award** – *sponsored by Neovii Pharmaceuticals*
- **Closing session**
 - **Nature Publishing Award for Best Clinical & Science Posters** - *sponsored by Nature Publishing Group*
- **Nurses Group closing session**
 - **Best Oral presentation**
 - **Best Poster**

Upcoming Annual Meetings



- **42nd Annual Meeting, Valencia**
 - 2 - 6 April, 2016
 - Congress President: Miguel Angel Sanz



- **43rd Annual Meeting, Marseille**
 - Date 2017 (tbc)
 - Congress President: Christian Chabannon

- Members will be invited shortly to submit a **bid to host the 2019 Annual Meeting**
- The mail of “Invitation to bid” will be sent to all EBMT Centres at the beginning of June 2015
- Eligibility criteria, bid specification document and overview of the EBMT Annual Meeting will be then available on the EBMT website
- If interested, please inform EBMT Executive Office in Barcelona
- **Submission deadline** for complete bid documents:
30 September 2015

**For more information, please visit the
education section on www.ebmt.org**



Acknowledgments to ...



To YOU EBMT members

... to the Board Members

Executive Committee

Anna Sureda – Secretary

Fred Falkenburg – Treasurer

Nicolaus Kröger - Scientific Council Chair

Rafael Duarte - Scientific Council Co-Chair

Dominique Farge Bancel - Scientific Council Education
Representative


Peter Dreger - Scientific Council Registry Representative

Aleksandra Babic - Nurses Group President

Taner Demirer, Muhit Özcan and Mutlu Arat - Congress Co-
Presidents and Congress Scientific Secretary



... the EBMT Staff



... the outgoing Treasurer

J.H.Frederik Falkenburg



... our 25 sponsors

Platinum



Silver



Bronze



Source: EBMT March 2015



EBMT Strategic plan 2014 - 2016

The process

- The process started in September 2013
- Participation of all EBMT stake holders: EBMT Members, Staff, Board Members, external advisors, etc.
- 6+2 pages document
- To be endorsed by the GA in Istanbul

The EBMT's vision

- Enhancing the **scientific output** through strong support for the working parties
- Collaborating with the different **disease-oriented cooperative groups**
- Widening the scope of the **Annual Meeting** through the incorporation of high level basic and translational research sessions
- Developing a **broad annual educational events agenda** to address more focused research and clinical topics
- Advocating for **patients** (including nursing) before the health authorities to maintain a high standard of care and high quality research

EBMT premier society in the world for research and collaboration in Stem Cell Transplantation, Cellular Therapy and other related fields such as Immunotherapy

Scientific context and Background

- Major advances related to breakthrough results achieved with newer immunotherapeutic agents and advanced cellular therapies
- Role of stem cell transplantation (whether autologous or allogeneic), is being refined and revisited
- Advent of new effective drugs for several diseases: what is the specific role of transplantation with or without novel agents in this new era?
- Cost of drugs is becoming an important matter of concern worldwide

1. Improve Study Management and Data Quality
2. Improve Clinical Trials processes to enable EBMT to conduct 1-2 new CT per year
3. Implement changes to Med-A and Med-B; consolidate donor follow-up
4. Enhance the scientific communication (studies, open access publications etc.) towards the EBMT community
5. Finalize the Registry Upgrade project
6. Promote the use of the Registry to centers that are still submitting paper forms

7. Introduce a mid-size specific educational event
8. Develop the Annual Congress concept, content and tools
9. Develop strategic partnerships with regional associations
10. Improve EBMT Education online content and resources
11. Maintain momentum of JACIE in Europe and develop stepped process for centres in LMICs

12. Raise funds to cover all financial needs without deficit and maintaining 80% mission ratio
13. Enhance partnership between EBMT and pharmaceutical companies
14. Develop membership perspectives, including new categories (young physicians) and provide more educational materials to our members
15. Design projects to raise funds from non-pharmaceutical companies



Financial Report 2014 Ernst & Young Management Letter 2014 Budget 2015

General Assembly, Istanbul, March 2014

Frederik Falkenburg



Financial Report 2014

Treasurer Financial Highlights

- After 3 years of governance and structural changes, we have succeeded in reducing the financial risks. Today, EBMT has mechanisms of control in place that demonstrate clear lines of accountability through transparency, which has resulted in an official audit of the financial statements by third party auditors during 2014.
- In 2014, EBMT has increased from 80% to 84% the expenses dedicated to its Mission (Studies, Registry, Accreditation and Education) and the reduced to 16% the expenses allocated to Management (Board and Executive Office expenses)
- EBMT will end the year with a total surplus of 141K€. The 2014 surplus will be returned to the reserves which will strengthen the financial position of EBMT. This financial situation therefore allows an increase in personnel to be allocated to scientific studies, which will be overseen by the Working Parties in 2015.

Income

Summary	2012	2013	2014
	Dec	Dec	Dec
01 Structural	1.883.415	2.063.870	2.385.825
02 Studies & Education & Accreditation	1.276.749	526.235	938.193
03 Others	72.082	315.923	153.321
	3.232.246	2.906.028	3.477.339

Expenses

Summary	Final '12	2013	2014
	Dec	Dec	Dec
01 WP	160.054	176.000	149.483
02 Divisions & Committees	100.557	61.476	74.924
03 Units	3.028.538	2.528.165	2.666.313
04 Others	61.389	304.480	391.651
Total	3.350.538	3.070.120	3.282.371

Net Result

	Final '12	2013	2014
	Dec	Dec	Dec
Income	3.232.246	2.906.028	3.477.339
Costs	3.350.538	3.070.120	3.282.371
Earmarked			53.490
Result	118.292-	164.092-	141.477

Income 2014

SOURCE of INCOME

in 1,000€

Membership

Sponsoring

Annual Meeting

Others

Non-earmarked Income

Studies & CT & Education

Accreditation (JACIE)

Other Grants

Earmarked Income

TOTAL Income

2013

Result

%

565 19%

470 16%

983 34%

59 2%

2.078 71%

370 13%

165 6%

293 10%

828 29%

2.906 100%

2014

Result

in K€ %

556 16%

490 14%

1.220 35%

120 3%

2.386 69%


646 19%

292 8%

153 4%

1.092 31%

3.477 100%




■ Non-earmarked Income ■ Earmarked Income

Expenses 2014

HOW EBMT SPENDS THE MONEY

in 1,000€

	2013		2014	
	Result		Result	
Retrospectives Studies	771	25%	911	28%
Prospective Studies	383	12%	367	11%
Educational Activities	176	6%	149	5%
EBMT Registry	497	16%	506	15%
Accreditation Process (JACIE)	301	10%	363	11%
Nurses Activities	51	2%	65	2%
Committees Activities	10	0%	10	0%
Provision Reg Upgr & Personnel			365	11%
Registry Upgrade	251	8%	21	1%
Total Mission	2.440	79%	2.758	84%
Management & Administration	630	21%	525	16%
TOTAL Cost	3.070	100%	3.282	100%



Provisions 2014



Concept	Amount
Registry Upgrade Donors	215,000
EBMT Staff	50,000 Statistical Support 50,000 Maternity Leave 50,000 Staff Liabilities

Balance 2014

BALANCE

(financial situation at the end of the year)

2013

2014

in 1,000€

Cash & equivalents	2.263	47%
Other current assets	2.572	53%
Total Net Assets	4.835	100%

3.073	50%
3.046	50%
6.119	100%

Earmarked funds	408	8%
Non-earmarked funds	2.126	44%
Provision	79	2%

462	8%
2.267	37%
417	7%

Total Reserves	2.613	54%
-----------------------	--------------	------------

3.146	51%
--------------	------------

Current Liabilities	2.222	46%
---------------------	-------	-----

2.973	49%
-------	-----

Total Liabilities and Reserves	4.835	100%
---------------------------------------	--------------	-------------

6.119	100%
--------------	-------------

Reserves and provisions end of 2014

(financial situation at the end of the year)

2013

2014

in 1,000€

Earmarked reserves	408	462
Non-earmarked reserves	2.126	2.267
Provision	79	417
Total Reserves	2.613	3.146



Ernst & Young Management Letter & Audit Report 2014

Ernst & Young Report 2014

- Although EBMT is not required by law to have a third party audit, the EBMT has performed one in 2014.
- For 2013 we determined that some uncertainties in the reporting still existed, which lead to an independent auditor's report with a disclaimer.
- Today, the control framework is fully completed and implemented in the EBMT.
- EBMT has changed the awareness and behavior of the employees within EBMT regarding internal control procedures
- EBMT was awarded a qualified report for 2014.
- Further work and time is required to fully consolidate the TAX Framework

	Our impression In 2014	Our impression In 2013	Our impression In 2012
Governance and compliance	No risk	L	H
Financial statement closing process	No risk	L	H
Internal control process	No risk	M	H
Tax:			
• Value Added Tax (VAT)	M	H	H
• Wage Tax	L	M	H
• ANBI (public benefit organisation)	No risk	M	M
• CIT (corporate income tax)	M	M	M
Treasury	L	M	H
Expenditures	L	M	H
Revenues:			
• Annual Meeting	No risk	No risk	H
• Clinical Trials	L	M	H
• Accreditation Fee	L	M	H
• Memberships	No risk	No risk	M
• Research Projects	L	L	H
• Sponsoring	No risk	No risk	M
Personnel	L	M	H
Automation	M	M	H





Budget 2015

Budget 2015

Income

2015

Summary

01 Structural	2.160.000	
02 Studies & Education & Accreditation	1.306.064	
03 Others	250.000	
	3.716.064	

Expenses

2015

Summary

01 WP	176.000	
02 Divisions & Committees	60.000	
03 Units	3.269.724	
04 Others	210.000	
Total	3.715.724	

Net Result

2015

Income	3.716.064	
Costs	3.715.724	
Earmarked Reserves		
Result	340	



Financial Committee Recommendations

Jan Cornelissen & Charles Craddock

The Financial Committee

- Approves the financial report 2014.
- Appreciates the major improvements in governance and financial control



- Approval of the General Assembly for:
- Financial report 2014
- Re-appoint Jan Cornelissen en Charles Craddock as Financial Committee



Secretary's Activity Report

Membership Survey Results

Election and re-elections results

Anna Sureda

Istanbul – Tuesday 24 March 2015



Secretary's Activity Report

Membership Overview

Global figures

- The EBMT has a total of **4,610 Members** (Centres & Individuals) with the following split per role

Role	Number
Physician[1]	2704
Nurse[10]	778
Data Management[3]	722
Lab technician[6]	105
Quality manager[5]	157
Other[77]	144
	4610

CENTRES Membership Overview

Global figures

	GAM 2015	<i>vs GAM 2014</i>
Number of EBMT Centres	568	568
Of which PROVISIONAL centres	16	12
Of which FULL centres reporting	490	495
Of which ASSOCIATE centres	62	61

CENTRES Membership Overview

Per country

- The **568** EBMT centres are located in **57 different countries**
- The top **10** split of Centres represents **420** Centres (74% of total) and the split per countries is the following :

	Country	Numbers of centres GAM 2015	Numbers of centres GAM 2014
Nº1	Italy	86	85
2	Germany	82	80
3	U.K.	52	52
3	France	52	51
5	Spain	46	47
6	Turkey	39	35
7	Poland	18	18
8	Belgium	18	18
9	The Netherlands	15	14
10	Switzerland	12	11

CENTRES Membership Overview

New EBMT Members

- The following **16** Member Centres have been granted **provisional membership** and await for your approval.

CIC	Institution	City	Country
125	St Johannes-Hospital	Dortmund	Germany
141	USD Trapianti di Midollo, Adulti	Brescia	Italy
167	National Taiwan University Hospital	Taipei	Taiwan
262	Universite Paris IV, Hopital la Pitié-Salpêtrière	Paris	France
388	St. Vincent's Hospital, Kinghorn Cancer Centre	Sydney	Australia
434	Singapore General Hospital	Singapore	Singapore
443	Peking University People's Hospital	Beijing	China
444	King Abdul - Aziz Medical City	Riyadh	Saudi Arabia
445	Istanbul Medipol University,	Istanbul	Turkey
446	Istanbul Medipol University,	Istanbul	Turkey
447	Helios Klinik Schwerin	Schwerin	Germany
448	Medical Park Bahcelievler Hospital	Istanbul	Turkey
449	National Center for Cancer Care & Research	Doha	Qatar
454	Adana Acibadem Hospital	Adana	Turkey
603	John Radcliffe Children's Hospital	Oxford	United Kingdom
638	Hospital Hirslanden	Zürich	Switzerland

CENTRES Membership Overview

Centres Membership Status Changes

The following number of member centres have had their membership status changed due to data reporting:

- **Full to Associate:** **8**

8 Centres have stopped reporting and have been moved from Full Members to ASSOCIATE

- **Associate to Full:** **4**

4 centres have resumed reporting and have been moved from Associate to FULL

INDIVIDUAL Membership Overview

Main figures

	GAM 2015	Vs GAM 2014
Individual Membership	80	77
<i>Of which PROVISIONAL</i>	18	9
<i>Physicians</i>	31	40
<i>Nurses</i>	31	28
Honorary Members	28	26

INDIVIDUAL Membership Overview

New EBMT Individual Members

- The following 18 Individuals have been granted **provisional membership** and await for your approval.

Surname	Name	Role	Country
Avcin	Simona Lucija	Physician	Slovenia
Boglione	Claudia	Nurse	Italy
Boodhoo	Asswade	Nurse	United Kingdom
Borda Molina	Andres Armando	Physician	Colombia
Butler	Andrew	Physician	New Zealand
Ciccocioppo	Rachele	Physician	Italy
Degen Kellerhals	Sabine	Nurse	Switzerland
Girardi	Daniele	Nurse	Italy
Hamsar	Hanan Naveed	Nurse	Pakistan
Kerezsi	Katalin	Nurse	Hungary
Khan	Hussna	Nurse	Pakistan
Khojah	Osamah Tawfiq A.	Physician	Saudi Arabia
Madatha	Vijay Ramanan	Physician	India
Magaro	Antonio	Principal Nurse	Italy
Morris	Curly	Physician	Ireland
Ncube	Thobekile	Nurse	United Kingdom
Schroder	Teija	Nurse	Finland
Van Hoef	Marlies	Physician	Switzerland



Membership Survey Results

Survey

- Outstanding **level of participation**:
 - 668 responding members
(compared to 506 in 2010)
 - representing 439 Centers from 55 countries.
- **Thank you** to all Members for their time in responding and bringing ideas to this survey



Results by topics (1/3)

SCIENCE

- The EBMT **Working Party structure** represents the right framework in which to perform studies
- EBMT studies are **open** to every interested stakeholder
- Members would like to be **increasingly involved** in such scientific activities
- Need to **increase level of communication** about ongoing studies

ANNUAL MEETING

- Expectations for more innovative & “practical” sessions :
 - New types of sessions at EBMT2015: “Meet the experts”, “How do I do? sessions” and Lunch Controversies with additional topics

EDUCATION

- Smaller and more focused EBMT-driven educational/scientific meetings/workshops, with topics related to clinical practice
 - More **educational support**: free access to recommendations and guidelines; electronic versions of presentations made during the annual meeting
 - New **educational tools**: quizzes, multiple choice questions, quick tips, etc. to transfer the “know how” to junior colleagues.
- These ideas will be a major focus of the educational projects in the next couple of years

Results by topics (3/3)

QM STANDARDS & ACCREDITATION

- Important parts of transplantation practice and care
 - More **training and support** with:
 - enhanced networking
 - sharing of experiences
 - access to expertise
- ... would help non-accredited centers to engage with the JACIE accreditation process.
- Work on innovative ideas to facilitate the accreditation process to most candidates.

NURSES

- Expectation for an **increased role** for Nurses within the EBMT
 - EBMT should facilitate and encourage more nurses to perform **Nursing Research**
 - Need for additional **educational tools and training resources**
- The Nurses Group is actively working on these issues



Election result



EBMT Treasurer Candidate
Jürgen Kuball
(Total 140 responses)

YES	91% - (128 votes)
NO	4% - (5 votes)
NO VOTE	5% - (7 votes)



Re-election results

Complications and Quality of Life Working Party Chair



EBMT CQLWP Rafael Duarte (Total 140 responses)	
YES	89% - (125 votes)
NO	6% - (9 votes)
NO VOTE	4% - (6 votes)

Chronic Malignancies Working Party Chair



EBMT CMWP Nicolaus Kroeger (Total 140 responses)	
YES	93% - (130 votes)
NO	5% - (7 votes)
NO VOTE	2% - (3 votes)



Thank you!